Xencor Inc (XNCR) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$24.34

From 52W high−15.63%

Volume5.20M

Market cap$1.84B

P/E (TTM)—

P/S (TTM)17.5x

Div yield—

Key dataSep 18, 2026

Open

$24.34

From 52W high

−15.63%

Volume

5.20M

Market cap

$1.84B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.7x

P/E (TTM)

—

RSI (14)

50.3

MomentumView details →

1D Return

+0.53%

YTD Return

+60.94%

SummaryUpdated Jun 1, 2026

Xencor, Inc. (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Monrovia, California. The company went public in December 2013 and has established itself as a leader in engineered antibody therapeutics. Xencor specializes in developing innovative treatments for cancer and autoimmune diseases using its proprietary XmAb protein engineering platform, which creates enhanced monoclonal antibodies and cytokines with improved therapeutic properties compared to conventional treatments.

Ask drillr about Xencor Inc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−11.7x

EV/Sales

13.8x

P/S (TTM)

17.5x

P/B (TTM)

3.7x

ProfitabilityView details →

Gross Margin

43.31%

Net Margin

−155.59%

EBITDA Margin

−117.75%

ROE (TTM)

−32.46%

ROA (TTM)

−22.53%

Asset Turnover

0.14x

GrowthView details →

Revenue YoY

−36.05%

EPS YoY

+13.55%

FCF YoY

−47.91%

Revenue CAGR 3Y

−8.62%

EPS CAGR 3Y

+65.36%

EBITDA YoY

−14.29%

MomentumView details →

1D Return

+0.53%

YTD Return

+60.94%

1Y Return

+139.45%

RSI (14)

50.3

vs 50D SMA

+8.72%

vs 200D SMA

+58.97%

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

6.39x

Quick Ratio

6.39x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.29

EPS Surprise

63.82%

Beats (12Q)

7/12

Next Q EPS Est

−$0.38

Avg Surprise (4Q)

19.00%

Rev Surprise

171.16%

Financials snapshotView financials →

Revenue (TTM)

104.97M

Net Income (TTM)

−163.32M

Op. CF (TTM)

−205.81M

Next earningsNov 4, 2026 →

Latest newsMore news →

Xencor Inc reported Q2 2026 total revenue of $51.2 million, a 17.4% increase year-over-year, with a net loss of $21.7 million and diluted EPS of -$0.29.47d ago

Similar companies

Stoke Therapeutics, Inc.STOK Galapagos N.V.GLPG Mind Medicine (MindMed) Inc.MNMD 金迪克688670.SH Revolution Medicines, Inc. WarrantRVMDW Galapagos N.V. Sponsored ADRLKFT Find similar companies →

Latest newsMore news →

Xencor Inc reported Q2 2026 total revenue of $51.2 million, a 17.4% increase year-over-year, with a net loss of $21.7 million and diluted EPS of -$0.29.47d ago